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ABSTRACT
Objectives: Our study aimed to determine the epidemiological characteristics and diagnostic and treatment protocols of 
primary vaginal carcinoma. Also, we compared the clinical and pathological features of primary vaginal carcinoma which 
intersect with cervical and vulvar carcinomas.
Material and methods: Sixteen patients with primary vaginal carcinoma, admitted to the Department of Gynecologic 
Oncology, Izmir Tepecik Training and Research Hospital between January 1983 and December 2012, were evaluated 
retrospectively. FIGO (International Federation of Gynecology and Obstetrics) Surgical staging was performed. The SPSS 
(Statistical Package for Social Sciences) program was used for statistical analyses.
Results: The histological distribution of the 16 patients with primary vaginal carcinoma was as follows: 9 patients (56.3%) 
with squamous cell carcinoma (SCC), 5 (31.3%) with rhabdomyosarcoma, and 2 (12.5%) with adenocarcinoma.
Conclusion: The stage of the disease was found the be the main factor affecting the survival.
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INTRODUCTION
Primary vaginal cancer is a rare tumor of the female 
genital system as vaginal tissue is relatively resistant to 
malignant change. Primary vaginal cancer, first identified 
as a distinct type of cancer in 1952 by Graham and Meigs 
[1], accounts for approximately 1–2% of all gynecologic tu-
mors [2]. The incidence of invasive vaginal cancer has been 
estimated at 0.42 per 100,000 women, and has remained 
stable since the 1980s [3]. Interestingly, malignancies, at 
both ends of the vaginal tract, are more often observed 
than vaginal malignant diseases. Metastatic cancers account 
for the vast majority (80–90%) of vaginal malignancies [4]. 
Sixteen percent of vaginal cancers are primary, while 84% 
are metastatic. Twenty-seven percent of vaginal squamous 
cell carcinoma (SCC) cases are primary. However, 83% were 
found to be metastatic from the cervix or the vulva [5–7]. 
SCC accounts for the majority of the primary lesions. Mela-
noma, sarcoma, and adenocarcinoma have been described 
in primary cancers as well. Sarcomas sometimes occur after 
radiotherapy for cervical cancer [8, 9]. If cervical and vagi-
nal involvement is detected together, it is assumed to be 
primary cervical carcinoma, whereas if vulvar and vaginal 
involvement is determined together, the cancer is assumed 
to be primary vulvar malignancy. Therefore, primary vaginal 
cancer is found in an extremely limited number of cases and 
is accompanied by the uncertainty of the primary diagnostic 
criteria. Two criteria are required in order for cancer to be 
accepted as primary, i.e. no pathology in the cervix or the 
vulva, and histopathological findings different from uterine 
tumors if hysterectomy was performed for uterine tumors 
within 5 years [10]. Due to the scarcity of primary vagi-
nal cancers and the uncertainty of the primary diagnostic 
criteria, the clinical and pathological features, as well as 
the diagnostic and treatment protocols of primary vaginal 
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cancer remain unclear. The aim of the study was to evaluate 
the clinical and pathological features, as well as treatment 
and prognosis of primary vaginal cancer, and to compare 
them with the literature.
MATERIAL AND METHODS
Sixteen patients with primary vaginal carcinoma, ad-
mitted to the Department of Gynecologic Oncology, Izmir 
Tepecik Training and Research Hospital between January 
1983 and December 2012, were evaluated retrospectively. 
Patients were evaluated for age, gravidity, parity, tumor 
markers, pathology results, operation types, whether or 
not they received postoperative adjuvant therapy, progno-
sis, and death rate. FIGO staging was performed. The SPSS 
(Statistical Package for Social Sciences) program was used 
for statistical analyses. All data are presented in tables. OS 
and pelvic failure-free survival (PFFS) were estimated using 
the Kaplan-Meier method with two-sided log-rank test. 
Multivariate analyses were performed using the Cox propor-
tional hazard model. The p-value of < 0.05 was considered 
as statistically significant for all tests.
RESULTS
The histological distribution of the 16 patients with 
primary vaginal carcinoma was as follows: 9 patients 
(56.3%) with SCC, 5 (31.3%) with rhabdomyosarcoma, and 
2 (12.5%) with adenocarcinoma. Mean patient age was 
52.87 ± 7.83 at diagnosis. The age distribution was between 
18 and 89 years. The most common complaints included 
vaginal bleeding and vaginal discharge. Mean menstruation 
time was 35 years. Parity distribution was between 1 and 
6 (mean 3.27 ± 1.61) in the SCC group, and between 0 and 
8 (mean 3.33 ± 1.95) in the group with other histological 
types. Also, three infertile patients were detected in the 
group with other histological types. Coexisting diabetes and 
hypertension were observed in 2 (22.2%) patients with SCC, 
whereas 1 (14.3%) patient with hypertension and 1 (14.3%) 
with diabetes were found in the group with other histologi-
cal types. Two (22.2%) patients in the SCC group received 
the diagnosis of cervical cancer and received treatment, 
whereas in the group with other histological types 1 patient 
(14.3%) was diagnosed with cervical cancer and received 
treatment. Demographic characteristics of the patients are 
presented in Table 1.
All patients underwent surgical treatment. Radical hys-
terectomy/vaginectomy surgeries were performed in all 
9 patients (100%) from the SCC group. Two (28.6%) patients 
had a partial vaginectomy, and 1 patient underwent pelvic 
exenteration in the group with other histological types. The 
rate of patients without metastasis was 77.8% in the SCC 
group but the rate of inguinal lymph node metastasis was 
found to be 2%. In the group with other histological types, 
the rate of patients without metastasis was 71.4%, pelvic 
lymph node metastasis rate was 14.3%, and the inguinal, 
pelvic, and para-aortic lymph node metastasis rate was 
14.3%. When postoperative pathology was examined, the 
superiority of SCC histology was clearly visible. As far as the 
operation grade was concerned, grade 3 was observed in 
55.6% and 57.1% of the subjects from the SCC group and 
the other histological types group, respectively. Patients 
in both groups had more advanced grade on histopathol-
ogy exam. As for location, it was found that the lesions 
Table 1. Demographic characteristics of the patient
SCC Non-SCC
No % No %
Age (years)
≤ 40 1 11.1 3 42.9
41–50 – – 1 14.3
51–60 3 33.3 – –
61–70 – – 2 28.6
≥ 71 5 55.6 1 14.3
Parity
Nulliparity – – 3 42.9
Multiparity 9 100 4 57.1
Complaint
Vaginal discharge 3 33.3 1 14.3
PMB 1 11.1 1 14.3
V. bleeding 3 33.3 2 28.6
Mass fullness – – 2 28.6
Prurigo 2 22.2 – –
Pain – – 1 14.3
Diabetes – – 1 14.3
Hypertension – – 1 14.3
DM+HT 2 22.2 – –
Other malignites
Servix ca 2 22.2 1 14.3
Others – – 1 14.3
Risk factors
No 3 33.3 5 71.4
HPV 1 11.1 – –
Cigarette 2 22.2 1 14.3
HPV + cigarette 2 22.2 – –
HPV + cigarette + alcohol 1 11.1 – –
V. irritation – – 1 14.3
Hysterectomy history
(–) 6 66.7 6 85.7
(+) 3 33.3 1
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originated in the upper third of the posterior vaginal wall. 
When assessing lymphovascular invasion, 44.4% and 57.1% 
cases were found in the SCC group and the other histologi-
cal types group, respectively. We found that 66.7% of the 
patients in the SCC group were stage I, and 57.1% of the 
group with other histological types were stage IV. It was 
also observed that 44.4% of the patients in the SCC group 
underwent only radiotherapy, 11.1% only chemotherapy 
(12 cycles of carboplatin, 3 cycles of 5-FU), and 33.3% 
chemoradiation as the adjuvant therapy. Chemoradiation 
and radiotherapy were applied to 42.9% and 14.3% of the 
patients in the other histological types group. Recurrence 
was detected in 5 (55.6%) patients from the SCC group and 
5 (71.5%) patients from the other histological types group. 
Distant metastases in the SCC group were not observed, 
but 4 patients in the other histological types group showed 
metastasis to the bladder and the rectum. Surgical stage 
and morphological characteristics of the study population 
are presented in Table 2.
DISCUSSION
Primary vaginal cancer is a rare malignant disease, con-
stituting 1–2% of genital tumors in women [2]. SCC of the 
vagina is the most common histological type, and its fre-
quency is estimated at 85% [12–14]. Histological features 
of the patients enrolled in our study were consistent with 
the literature. Primary vaginal cancer is often observed in 
women over the age of 60 and peaks in the range of 70– 
–80 years. Only 30% of the affected patients are diagnosed 
before the age of 60 [5]. In our study, mean patient age 
was consistent with the literature, but the percentage of 
patients ≥ 71 years of age was 14.3% in the SCC group and 
55.6% in the other histological types group. Also, 42.9% of 
the patients in the other histological types group and 11.1% 
in the SCC group were < 40 years of age. While advanced 
patient age correlates with recurrence, it is inversely related 
with disease-free survival (DFS) and overall survival (OS). In 
our study, patient age and DFS and OS were not significantly 
correlated.
The etiology of vaginal carcinoma is the same as cervi-
cal cancer. Multiple sexual partners, smoking, alcohol use, 
sexual intercourse at an early age, and poor socioeconomic 
status are considered to be risk factors for vaginal cancer 
[5–7]. SCC of the vagina was found to be more related with 
these parameters as compared to the other histological 
types group, which is consistent with the literature.
Numerous studies have examined the relationship 
between parity and vaginal carcinoma, but no significant 
association was found [5–7, 11]. Parity was higher in the 
SCC group than the other histological types group, but the 
difference was not statistically significant.
Although the role of metabolic diseases such as obesity, 
diabetes, and hypertension in the pathogenesis of endome-
trial cancer has been confirmed, the same relationship is 
unclear for vaginal cancer. Previous hysterectomy, endome-
Table 2. Surgical stage and morphological characteristics of the patients
SCC Non-SCC
No % No %
Histological type
SCC 9 56.3 – –
Rabdomyosarkoma – – 5 31.3
Adenocarsinoma – – 2 12.5
Figo stage
0 1 11.1 – –
I 6 66.7 2 28.6
II 2 22.2 1 14.3
III – – – –
IV – – 4 57.1
N stage
N0 7 77.8 5 71.4
N1 2 22.1 2 28.6
M stage
M0 9 100 3 42.9
M1 – – 4 57.1
Tumour size
1–2 cm 2 22.2 – –
3–4 cm 4 44.4 – –
>5 cm 3 33.3 7 100
Localization
Vagen upper 1/3 7 77.8 6 85.7
Vagen middle 1/3 1 11.1 1 14.3
Vagen lower 1/3 1 11.1 – –
Vagen ant. 1 11.1 2 28.6
Vagen post. 7 77.8 4 57.1
Vagen lat. 1 11.1 1 14.3
Surgery 9 100 7 100
Chemotherapy 1 11.1 – –
Radiotherapy 4 44.4 1 14.3
KT + RT 3 33.3 3 42.9
Recurrence
No 4 44.4 2 28.6
Stumph 2 22.2 2 28.6
Vagina 2 22.2 2 28.6
Pelvic 1 11.1 1 14.3
Survival (months)
OS 27.78 ± 17.04 56.43 ± 37.83
DFS 18.44 ± 16.49 35.14 ± 30.98
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triosis, chronic irritation, and cervical or vaginal radiotherapy 
are also among the risk factors. Three patients (33.3%) in the 
SCC group and 1 patient (14.3%) in the other histological 
types group underwent hysterectomy for benign reasons.
The stage is the most important prognostic factor in vagi-
nal cancer. Epidemiology Survey Results (SEER) data give im-
portant information about the prognostic factors of primary 
vaginal cancer. Age, lymph node involvement, and tumor size 
are considered poor prognostic factors at diagnosis. On the 
other hand, the histological type of vaginal cancer has been 
reported as the most important factor but the significance 
of the grade remains to be fully elucidated. In our study, 
grade 3 differentiation rate was 55.6% and 57.1% in the SCC 
group and in the other histological types group, respectively. 
The majority of patients in both groups had high-grade le-
sions. There was no statistically significant difference between 
stage and patient age in either group (p > 0.05). 
According to the SEER data, if the tumor diameter 
is < 4 cm, the 5-year survival is 84%. If tumor diameter 
is > 4 cm, the 5-year survival is 65%. In our study, there was 
no statistically significant relationship between survival 
and tumor size. Squamous cell histology is seen in more 
early-stage tumors, whereas other histological types are 
often detected in the advanced stages (SEER). Stage 0–I was 
detected in 77.8% of the subjects in the SCC group, while 
28.6% of the patients in the other histological types group 
had stage II tumors and 57.1% had stage IV tumors. This 
ratio is consistent with the general literature and SEER data.
Lymphovascular invasion (LVSI), regardless of histologi-
cal grade or stage, is a powerful indicator of tumor recur-
rence and death. Vascular invasion suggests the presence of 
lymph node metastasis. In our study, DFS was significantly 
lower in the SCC group as compared to other histological 
types group if LVSI was present (p < 0.05).
There is no consensus in the literature regarding the 
treatment of primary vaginal cancer. Treatment should ad-
dress individual characteristics of the patient, i.e. age, gen-
eral medical condition, stage, and tumor location. Although 
radiotherapy is recommended as the standard treatment 
for all stages in many centers, surgical treatment is a better 
solution for early-stage disease in terms of survival [15–17]. 
Radical hysterectomy, vaginectomy, and pelvic lymph node 
dissection are the current approaches to treating vaginal 
cancer [12, 13, 16, 17]. Vaginal cancer management has not 
been standardized because prospective studies on the pos-
sible treatment of vaginal cancer have not been conducted. 
There are no uniform treatment options, and a highly indi-
vidualized treatment is necessary. The generally accepted 
standards of radical surgical modality include: 
 Ū partial vaginectomy with adequate surgical mar-
gins + pelvic lymphadenectomy ± hysterectomy for 
mass located in the superior part of the vagina, 
 Ū radical vaginectomy with vulvectomy and inguinal lym-
phadenectomy for vaginal lesions located in the inferior 
part of the vagina, 
 Ū radical vaginectomy + pelvic lymphadenectomy + elec-
tive inguinal lymphadenectomy (only palpable inguinal 
nodes) are recommended for lesions located in the mid-
dle part of the vagina [12, 16, 18]. 
All patients in our study underwent radical surgery: 
44.4% in the SCC group underwent only radiotherapy, 11.1% 
only chemotherapy (12 cycles of carboplatin, 3 cycles of 
5-FU), and 33.3% chemoradiation as the adjuvant therapy. 
Chemoradiation was applied to 42.9% and radiotherapy 
was applied to 14.3% of the patients in the other histologi-
cal types group. 
CONCLUSIONS
The stage of the disease constitutes the primary fac-
tor influencing DFS and OS. We could not reach statisti-
cally significant conclusions whether age, parity, or age 
at menarche and menopause are risk factors for vaginal 
cancer. Thus, medical history of the patients and our find-
ings were analyzed and compared with the literature. The 
evaluated parameters were consistent with the literature. 
We concluded that there is a need for more extensive and 
multicenter studies to achieve valid results because of the 
limited number of cases with vaginal cancer.
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